▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1994 by analyst upside · 2026-06-27
THC
Tenet Healthcare Corporation
Healthcare · Market Cap $16B · P/E 9.8x
ANALYST PRICE TARGET
+28.7%
implied upside to consensus target
Current Price $189.0
Consensus Target $243.19
Bull Target $288.0
Bear Target $210.0
Analysts Covering 21
ANALYST CONSENSUS — BUY
Strong Buy
6
Buy
13
Hold
2
Sell
0
52-Week Low $146.6
52-Week High $247.21
YTD Return -5.2%
FUNDAMENTALS
Market Cap $16B
P/E Ratio (TTM) 9.8x
Forward P/E 10.7x
EPS (TTM) $19.22
PEG Ratio 4.51
Dividend Yield N/A
Revenue (TTM) $21.5B
Profit Margin 7.9%
52-WEEK RANGE
52-Week Low $146.6
52-Week High $247.21
Current Price $189.0
Bear Target $210.0
Bull Target $288.0
● Now $189.0 ● Target $243.19
TRADING DATA
Avg Volume 1.4M
YTD Return -5.2%
Analyst Count 21
Consensus Buy
Upside to Target +28.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Tenet Healthcare Corporation (THC) is currently trading at $189.0 with a Wall Street consensus price target of $243.19, implying potential upside of 28.7% over the next 12 months. 21 analysts currently cover THC, with a consensus rating of Buy — 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $288.0, while the most cautious has a target of $210.0.

THC operates in the Healthcare sector with a market capitalisation of $16B. The stock is down 5.2% year-to-date and is currently trading near the lower end of its 52-week range of $146.6 – $247.21.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GMAB +41.0%
Genmab A/S
$16B · P/E 19.9x · Buy
NBIX +15.3%
Neurocrine Biosciences, Inc.
$17B · P/E 25.9x · Buy
SNN +16.5%
Smith & Nephew plc
$13B · P/E 21.0x · Hold
STE +19.1%
STERIS plc
$21B · P/E 27.2x · Buy
ZBH +6.0%
Zimmer Biomet Holdings, Inc.
$18B · P/E 23.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for THC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Overweight → Overweight 2026-05-05 Building track record
Baird — Reiterated
Neutral → Neutral 2026-05-05 Building track record
Stephens & Co. — Reiterated
Overweight → Overweight 2026-05-04 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-01 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-05-01 62% win rate (8 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-01 Building track record
Keybanc — Reiterated
Overweight → Overweight 2026-05-01 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-03-12 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →